Session » Spondyloarthritis Including PsA – Basic Science Poster

Date: Sunday, November 13, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1152

A Novel Serological Biomarker Measuring a Fragment of Cartilage Intermediate Layer Protein 1 Is Highly Upregulated in Rheumatic Diseases

1:00PM-3:00PM: Abstract Number: 1154

Axial Spondyloarthritis: Profiling of MiRNAs in Peripheral Blood Mononuclear Cells

1:00PM-3:00PM: Abstract Number: 1157

Bacterial Indole Associated with Spondyloarthritis-Related Dysbiosis Contributes to Enhanced Th17 Immunity

1:00PM-3:00PM: Abstract Number: 1151

Colonic Organoids to Study the Role of HLA-B27 in Gastrointestinal Epithelial Biology

1:00PM-3:00PM: Abstract Number: 1158

Differential Plasma Levels of S100 Proteins in Male versus Female Patients with Ankylosing Spondylitis

1:00PM-3:00PM: Abstract Number: 1153

Differentially Expressed Genes in Males and Females with Ankylosing Spondylitis (AS): Transcriptomics of IL-17-producing Cells in Patients with AS

1:00PM-3:00PM: Abstract Number: 1155

Epigenome-Wide Integrative Association Study on Spondyloarthritis and Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 1164

Expanded CD8+ T Cell Clones from HLA-B*27-positive Patients with Spondyloarthritis Show Signs of Antigen-experience

1:00PM-3:00PM: Abstract Number: 1161

IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 1162

Improvement of Gut Microbiota Dysbiosis in Patients with Axial Spondyloarthritis After One Year of Biological Treatment

1:00PM-3:00PM: Abstract Number: 1160

Mapping Spondyloarthritis Susceptibility Loci in B10.RIII Mice

1:00PM-3:00PM: Abstract Number: 1165

Pathogenicity of IL-17 Producing Cells in HLA-B27 Transgenic Rat Model of Spondyloarthritis

1:00PM-3:00PM: Abstract Number: 1163

Proteomic Investigation to Identify Urinary Biomarker for Ankylosing Spondylitis

1:00PM-3:00PM: Abstract Number: 1156

Serum Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Is Increased in Patients with Active Ankylosing Spondylitis (AS) and Persists Despite Anti-TNF Treatment

1:00PM-3:00PM: Abstract Number: 1150

Spatial Transcriptomics Stratifies Health and Psoriatic Disease Severity by Emergent Cellular Ecosystems

1:00PM-3:00PM: Abstract Number: 1159

Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Center

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].